- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06346054
Molecular Assessment for Gastro-Esophageal Cancer (MAGEC)
The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.
The main questions this study aims to answer:
Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.
Participants will provide a breath and blood sample during their routine standard of care visits.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stijn Vanstraelen, MD
- Phone Number: 0032 16346822
- Email: stijn.vanstraelen@kuleuven.be
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any breath or blood analysis
- >18 years old
- Barrett's esophagus or treatment naïve gastro-esophageal cancer stage I to IV
- Voluntary healthy controls
Exclusion Criteria:
- <18 years old
Patient has history of:
- Active other cancer than gastro-esophageal cancer
- Prior cancer treated <3 years ago
- Hepatic dysfunction/liver failure (MELT >7)
- Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the study plan.
- Insufficient/unreliable quality of breath (e.g., breath flow) or plasma sample (e.g., haemolytic sample)
- Incarcerated individuals
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gastro-esophageal cancer group
Participants with gastroesophageal cancer providing a breath and blood sample for biomarker identification
|
Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
|
Active Comparator: Barrett's esophagus group
Participants with Barrett's esophagus providing a breath and blood sample for biomarker identification
|
Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
|
Active Comparator: Healthy controls
Healthy controls providing a breath and blood sample for biomarker identification
|
Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of the concentrations of oncometabolites
Time Frame: year 1-2
|
Identify the concentrations of cancer-related metabolites (oncometabolites) in the exhaled breath and blood compared to healthy controls
|
year 1-2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of incidence of early-stage cancer
Time Frame: year 2-5
|
Distinguish early-stage gastro-oesophageal cancer from Barrett's esophagus and healthy controls based on sensitivity, specificity and accuracy of the oncometabolite concentration
|
year 2-5
|
Assessment of incidence of therapy response
Time Frame: year 2-5
|
Predict and assess therapy response prior to surgery, based on sensitivity, specificity and accuracy of the oncometabolite concentration
|
year 2-5
|
Assessment of percentage change of therapy response
Time Frame: year 2-5
|
Assess changes in the concentrations of the oncometabolites related to treatment.
|
year 2-5
|
Assessment of incidence of recurrence
Time Frame: year 2-5
|
Predict and assess recurrence, based on sensitivity, specificity and accuracy of the oncometabolite concentration
|
year 2-5
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stijn Vanstraelen, MD, Universitaire Ziekenhuizen KU Leuven
- Principal Investigator: Philippe Nafteux, MD, PhD, Universitaire Ziekenhuizen KU Leuven
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- s68669
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Breath analysis
-
Stanford UniversityCompletedSmall Cell Lung Cancer | Non-Small Cell Lung Cancer | Lung CancerUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownRespiratory Tract Infections | Hematologic DiseasesBelgium
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Recruiting
-
Tera GroupRecruiting
-
Scentech Medical Technologies LtdCompleted
-
Landon Pediatric FoundationCompletedPuerperal: [Major Infection] or [Sepsis]United States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)CompletedStage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Schillerhoehe HospitalCompletedLung Cancer | Chronic Obstructive Airway DiseaseGermany
-
University of EdinburghUniversity of Amsterdam; University of StrathclydeCompletedNon-alcoholic Fatty Liver DiseaseUnited Kingdom
-
Schillerhoehe HospitalRobert Bosch Gesellschaft für Medizinische Forschung mbHTerminatedBreast Cancer | Ovarian Cancer | Lung CancerGermany